London, June 13, 2026, 19:06 BST
- Reckitt Benckiser Group plc closed Friday at 4,638p, gaining 1.27%. The FTSE 100 added 1.63% for the day, according to AJ Bell’s one-day performance read.
- Reckitt Benckiser reported buying back 194,500 shares on June 11, paying a volume-weighted average price of 4,615.90p apiece.
- Reckitt’s next key moment is the half-year results on July 29, which will put its 2026 outlook to the test with investors.
Reckitt Benckiser Group plc shares climbed Friday, closing at 4,638p, up 58p or 1.27%. The FTSE 100 consumer-goods stock still trades far from its 52-week high of 6,522.92p. It’s above its 52-week low of 3,664p, but the recent gain hasn’t fixed the longer-term drop in sentiment.
Reckitt’s latest update focused on buybacks, not operations. The company said in a June 12 notice that it bought back 194,500 ordinary shares on June 11 from Deutsche Bank AG, London Branch. These shares will go into treasury. Such “own shares” deals can help EPS if profits hold and the share count drops. Following the buyback, Reckitt holds 38,688,655 treasury shares, leaving 635,317,097 shares outstanding, excluding treasury. Investegate
The shareholder return story is in focus. Reckitt is trading like an income stock as much as a growth name. Numbers from AJ Bell put the dividend yield at 4.65%, with a price-to-earnings ratio at 9.48. Dividend yield shows the yearly dividend as a percent of the share price. The price-to-earnings ratio is the share price against annual earnings. AJ Bell’s data showed the most recent dividend paid on June 12 at 127.80p. That’s one reason income investors are tracking Reckitt while the stock is still under pressure.
Reckitt’s operating numbers are a bit murky. In April, Chief Executive Kris Licht told investors that “Core Reckitt delivered Q1 LFL net revenue growth of 1.3%” and confirmed the group is keeping its “LFL net revenue guidance for 2026.” LFL—or like-for-like—cuts out disposals and currency changes to gauge underlying sales. Excluding seasonal over-the-counter medicine, Reckitt said sales growth was stronger at 3.1%. Reckitt
Bears say Reckitt left little margin for mistakes after the first quarter. Reuters reported in April that first-quarter core like-for-like growth missed analysts’ estimates and Reckitt warned first-half margins would be about 200 basis points lower year-on-year; a basis point is one-hundredth of a percentage point. Weak cold-and-flu demand, higher oil-linked costs, and geopolitical disruptions put pressure on results. The Mead Johnson baby-formula business also remains an overhang as the company weighs strategic options.
Analysts are still mostly positive on Reckitt, though there isn’t total agreement. According to LSEG data from Investors’ Chronicle, as of June 11 there were four Buy calls, nine Outperform, seven Holds and one Sell. The 12-month median price target sits at 6,200p, well above the last price at 4,638p. That points to potential upside, but the mix of Holds and a Sell suggests there’s still a debate about whether Reckitt’s cheaper shares are enough to offset risks around margins, categories and litigation.
July 29 half-year results are now the focus. Investors want to see if Europe picks up, if cold-and-flu comps level out, if Reckitt is absorbing higher input costs, and if the buyback and dividend can go ahead without cutting financial flexibility. On today’s reported numbers, Reckitt still looks selectively appealing for income and value buyers—the yield, buyback, and analyst targets are supportive. The risk is there, though. The discount isn’t just a market miss. It points to worries about growth, margins, and issues in non-core lines.
